bexobrutideg — IND submission
2026
Targeting 2026 IND submission for bexobrutideg in inflammatory and autoimmune indications with a new tablet formulationSource filing
catalyst calendar
NURIX THERAPEUTICS INC · Data as of 2026-10-25
2026
Targeting 2026 IND submission for bexobrutideg in inflammatory and autoimmune indications with a new tablet formulationSource filing